Trials / Conditions / Aggressive Non-Hodgkin Lymphoma

Aggressive Non-Hodgkin Lymphoma

18 registered clinical trials studyying Aggressive Non-Hodgkin Lymphoma — 2 currently recruiting.

Status	Trial	Sponsor	Phase
Terminated	A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies NCT05336409	Century Therapeutics, Inc.	Phase 1
Recruiting	CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin' NCT05260957	Lazaros Lekakis	Phase 2
Recruiting	Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Agg NCT04231877	University of Washington	Phase 1
Withdrawn	Testing the Safety of CB-5339 in Patients With Cancer NCT04372641	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lympho NCT03749018	David Bond, MD	Phase 2
Completed	Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma NCT03458260	The Lymphoma Academic Research Organisation	Phase 2
Suspended	Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma NCT03704714	Northwestern University	Phase 1 / Phase 2
Completed	Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas NCT03161054	Fondazione Italiana Linfomi - ETS	Phase 2
Terminated	Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelate NCT03246906	Fred Hutchinson Cancer Center	Phase 2
Completed	Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma NCT03035331	Mayo Clinic	Phase 1 / Phase 2
Completed	Phase I/Ib Study of Nivolumab & Veliparib in Patients With Advanced Solid Tumors & Lymphoma NCT03061188	Northwestern University	Phase 1
Active Not Recruiting	Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency NCT01787409	Mayo Clinic	N/A
Completed	Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell NCT01527045	Fred Hutchinson Cancer Center	Phase 2
Completed	Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patient NCT01251575	Fred Hutchinson Cancer Center	Phase 2
Completed	Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated NCT01231412	Fred Hutchinson Cancer Center	Phase 3
Completed	Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by NCT00789776	Fred Hutchinson Cancer Center	Phase 1 / Phase 2
Completed	Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer NCT00723099	Fred Hutchinson Cancer Center	Phase 2
Completed	Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treatin NCT00075478	Fred Hutchinson Cancer Center	Phase 3